デフォルト表紙
市場調査レポート
商品コード
1062009

世界のNSCLC標的薬ALK阻害剤市場:考察と予測 (2028年まで)

Global Targeted Drug ALK Inhibitors for NSCLC Market Insights and Forecast to 2028

出版日: | 発行: QYResearch | ページ情報: 英文 92 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.55円
世界のNSCLC標的薬ALK阻害剤市場:考察と予測 (2028年まで)
出版日: 2022年03月01日
発行: QYResearch
ページ情報: 英文 92 Pages
納期: 2~3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、NSCLC標的薬ALK阻害剤 (Targeted Drug ALK Inhibitors for NSCLC) 市場について調査しており、市場規模や動向の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 レポート概要

  • 調査範囲
  • 市場分析:タイプ別
    • 世界のNSCLC標的薬ALK阻害剤の市場規模成長率:タイプ別, 2017 VS 2021 VS 2028
    • Crizotinib
    • Ceritinib
    • Alectinib
    • Brigatinib
    • Lorlatinib
    • Other
  • 市場:アプリケーション別
    • 世界のNSCLC標的薬ALK阻害剤の市場規模成長率:アプリケーション別, 2017 VS 2021 VS 2028
    • Squamous Cell Carcinoma of NSCLC
    • Adenocarcinoma of NSCLC
    • Large Cell Carcinoma of NSCLC
  • 調査目的
  • 対象期間

第2章 世界の市場成長トレンド

  • 世界のNSCLC標的薬ALK阻害剤の市場展望 (2017-2028)
  • NSCLC標的薬ALK阻害剤の市場成長トレンド:地域別
    • NSCLC標的薬ALK阻害剤 市場規模:地域別: 2017 VS 2021 VS 2028
    • NSCLC標的薬ALK阻害剤の市場規模実績:地域別 (2017-2022)
    • NSCLC標的薬ALK阻害剤の市場規模予測:地域別 (2023-2028)
  • NSCLC標的薬ALK阻害剤 市場動向
    • NSCLC標的薬ALK阻害剤 業界動向
    • NSCLC標的薬ALK阻害剤 市場の促進要因
    • NSCLC標的薬ALK阻害剤 市場の課題
    • NSCLC標的薬ALK阻害剤 市場の抑制要因

第3章 競合情勢:主要企業別

  • 世界のNSCLC標的薬ALK阻害剤の上位企業:収益別
    • 世界のNSCLC標的薬ALK阻害剤の上位企業:収益別 (2017-2022)
    • 世界のNSCLC標的薬ALK阻害剤の収益シェア:企業別 (2017-2022)
  • 世界のNSCLC標的薬ALK阻害剤の市場シェア:企業タイプ別 (Tier 1, Tier 2, and Tier 3)
  • 企業ランキング:NSCLC標的薬ALK阻害剤の収益
  • 世界のNSCLC標的薬ALK阻害剤 市場集中度
    • 世界のNSCLC標的薬ALK阻害剤 市場集中度 (CR5 and HHI)
    • 世界の上位10・上位5企業: NSCLC標的薬ALK阻害剤の収益 2021
  • NSCLC標的薬ALK阻害剤の主要企業の本社および事業エリア
  • 主要企業 NSCLC標的薬ALK阻害剤の製品ソリューションおよびサービス
  • 市場参入時期: NSCLC標的薬ALK阻害剤 市場
  • M&A, 拡張計画

第4章 NSCLC標的薬ALK阻害剤 内訳データ:タイプ別

  • 世界のNSCLC標的薬ALK阻害剤の市場規模実績:タイプ別 (2017-2022)
  • 世界のNSCLC標的薬ALK阻害剤の市場規模予測:タイプ別 (2023-2028)

第5章 NSCLC標的薬ALK阻害剤 内訳データ:アプリケーション別

  • 世界のNSCLC標的薬ALK阻害剤の市場規模実績:アプリケーション別 (2017-2022)
  • 世界のNSCLC標的薬ALK阻害剤の市場規模予測:アプリケーション別 (2023-2028)

第6章 北米

  • 北米のNSCLC標的薬ALK阻害剤 市場規模 (2017-2028)
  • 北米のNSCLC標的薬ALK阻害剤 市場規模:タイプ別
    • 北米のNSCLC標的薬ALK阻害剤 市場規模:タイプ別 (2017-2022)
    • 北米のNSCLC標的薬ALK阻害剤 市場規模:タイプ別 (2023-2028)
    • 北米のNSCLC標的薬ALK阻害剤の市場シェア:タイプ別 (2017-2028)
  • 北米のNSCLC標的薬ALK阻害剤 市場規模:アプリケーション別
    • 北米のNSCLC標的薬ALK阻害剤 市場規模:アプリケーション別 (2017-2022)
    • 北米のNSCLC標的薬ALK阻害剤 市場規模:アプリケーション別 (2023-2028)
    • 北米のNSCLC標的薬ALK阻害剤の市場シェア:アプリケーション別 (2017-2028)
  • 北米のNSCLC標的薬ALK阻害剤 市場規模:国別
    • 北米のNSCLC標的薬ALK阻害剤 市場規模:国別 (2017-2022)
    • 北米のNSCLC標的薬ALK阻害剤 市場規模:国別 (2023-2028)
    • 米国
    • カナダ

第7章 欧州

  • 欧州のNSCLC標的薬ALK阻害剤 市場規模 (2017-2028)
  • 欧州のNSCLC標的薬ALK阻害剤 市場規模:タイプ別
    • 欧州のNSCLC標的薬ALK阻害剤 市場規模:タイプ別 (2017-2022)
    • 欧州のNSCLC標的薬ALK阻害剤 市場規模:タイプ別 (2023-2028)
    • 欧州のNSCLC標的薬ALK阻害剤の市場シェア:タイプ別 (2017-2028)
  • 欧州のNSCLC標的薬ALK阻害剤 市場規模:アプリケーション別
    • 欧州のNSCLC標的薬ALK阻害剤 市場規模:アプリケーション別 (2017-2022)
    • 欧州のNSCLC標的薬ALK阻害剤 市場規模:アプリケーション別 (2023-2028)
    • 欧州のNSCLC標的薬ALK阻害剤の市場シェア:アプリケーション別 (2017-2028)
  • 欧州のNSCLC標的薬ALK阻害剤 市場規模:国別
    • 欧州のNSCLC標的薬ALK阻害剤 市場規模:国別 (2017-2022)
    • 欧州のNSCLC標的薬ALK阻害剤 市場規模:国別 (2023-2028)
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • ロシア
    • 北欧

第8章 アジア太平洋地域

  • アジア太平洋地域 NSCLC標的薬ALK阻害剤 市場規模 (2017-2028)
  • アジア太平洋地域 NSCLC標的薬ALK阻害剤 市場規模:タイプ別
    • アジア太平洋地域 NSCLC標的薬ALK阻害剤 市場規模:タイプ別 (2017-2022)
    • アジア太平洋地域 NSCLC標的薬ALK阻害剤 市場規模:タイプ別 (2023-2028)
    • アジア太平洋地域 NSCLC標的薬ALK阻害剤の市場シェア:タイプ別 (2017-2028)
  • アジア太平洋地域 NSCLC標的薬ALK阻害剤 市場規模:アプリケーション別
    • アジア太平洋地域 NSCLC標的薬ALK阻害剤 市場規模:アプリケーション別 (2017-2022)
    • アジア太平洋地域 NSCLC標的薬ALK阻害剤 市場規模:アプリケーション別 (2023-2028)
    • アジア太平洋地域 NSCLC標的薬ALK阻害剤の市場シェア:アプリケーション別 (2017-2028)
  • アジア太平洋地域 NSCLC標的薬ALK阻害剤 市場規模:地域別
    • アジア太平洋地域 NSCLC標的薬ALK阻害剤 市場規模:地域別 (2017-2022)
    • アジア太平洋地域 NSCLC標的薬ALK阻害剤 市場規模:地域別 (2023-2028)
    • 中国
    • 日本
    • 韓国
    • 東南アジア
    • インド
    • オーストラリア

第9章 ラテンアメリカ

  • ラテンアメリカのNSCLC標的薬ALK阻害剤 市場規模 (2017-2028)
  • ラテンアメリカのNSCLC標的薬ALK阻害剤 市場規模:タイプ別
    • ラテンアメリカのNSCLC標的薬ALK阻害剤 市場規模:タイプ別 (2017-2022)
    • ラテンアメリカのNSCLC標的薬ALK阻害剤 市場規模:タイプ別 (2023-2028)
    • ラテンアメリカのNSCLC標的薬ALK阻害剤の市場シェア:タイプ別 (2017-2028)
  • ラテンアメリカのNSCLC標的薬ALK阻害剤 市場規模:アプリケーション別
    • ラテンアメリカのNSCLC標的薬ALK阻害剤 市場規模:アプリケーション別 (2017-2022)
    • ラテンアメリカのNSCLC標的薬ALK阻害剤 市場規模:アプリケーション別 (2023-2028)
    • ラテンアメリカのNSCLC標的薬ALK阻害剤の市場シェア:アプリケーション別 (2017-2028)
  • ラテンアメリカのNSCLC標的薬ALK阻害剤 市場規模:国別
    • ラテンアメリカのNSCLC標的薬ALK阻害剤 市場規模:国別 (2017-2022)
    • ラテンアメリカのNSCLC標的薬ALK阻害剤 市場規模:国別 (2023-2028)
    • メキシコ
    • ブラジル

第10章 中東・アフリカ

  • 中東・アフリカのNSCLC標的薬ALK阻害剤 市場規模 (2017-2028)
  • 中東・アフリカのNSCLC標的薬ALK阻害剤 市場規模:タイプ別
    • 中東・アフリカのNSCLC標的薬ALK阻害剤 市場規模:タイプ別 (2017-2022)
    • 中東・アフリカのNSCLC標的薬ALK阻害剤 市場規模:タイプ別 (2023-2028)
    • 中東・アフリカのNSCLC標的薬ALK阻害剤の市場シェア:タイプ別 (2017-2028)
  • 中東・アフリカのNSCLC標的薬ALK阻害剤 市場規模:アプリケーション別
    • 中東・アフリカのNSCLC標的薬ALK阻害剤 市場規模:アプリケーション別 (2017-2022)
    • 中東・アフリカのNSCLC標的薬ALK阻害剤 市場規模:アプリケーション別 (2023-2028)
    • 中東・アフリカのNSCLC標的薬ALK阻害剤の市場シェア:アプリケーション別 (2017-2028)
  • 中東・アフリカのNSCLC標的薬ALK阻害剤 市場規模:国別
    • 中東・アフリカのNSCLC標的薬ALK阻害剤 市場規模:国別 (2017-2022)
    • 中東・アフリカのNSCLC標的薬ALK阻害剤 市場規模:国別 (2023-2028)
    • トルコ
    • サウジアラビア
    • UAE

第11章 主要企業のプロファイル

  • Pfizer
  • Novartis
  • Chugai Pharmaceutical (Hoffmann-La Roche group)
  • ARIAD Pharmaceuticals (Takeda)
  • Genvio Pharma Limited
  • Beacon Pharma Limited
  • Drug International Limted
  • Incepta Pharmaceuticals

第12章 アナリストによる分析/結論

第13章 付録

図表

LIST OF TABLES

List of Tables

  • Table 1. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028
  • Table 2. Key Players of Crizotinib
  • Table 3. Key Players of Ceritinib
  • Table 4. Key Players of Alectinib
  • Table 5. Key Players of Brigatinib
  • Table 6. Key Players of Lorlatinib
  • Table 7. Key Players of Other
  • Table 8. Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
  • Table 9. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
  • Table 10. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2017-2022) & (US$ Million)
  • Table 11. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Region (2017-2022)
  • Table 12. Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Region (2023-2028) & (US$ Million)
  • Table 13. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Region (2023-2028)
  • Table 14. Targeted Drug ALK Inhibitors for NSCLC Market Trends
  • Table 15. Targeted Drug ALK Inhibitors for NSCLC Market Drivers
  • Table 16. Targeted Drug ALK Inhibitors for NSCLC Market Challenges
  • Table 17. Targeted Drug ALK Inhibitors for NSCLC Market Restraints
  • Table 18. Global Targeted Drug ALK Inhibitors for NSCLC Revenue by Players (2017-2022) & (US$ Million)
  • Table 19. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Players (2017-2022)
  • Table 20. Global Top Targeted Drug ALK Inhibitors for NSCLC by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug ALK Inhibitors for NSCLC as of 2021)
  • Table 21. Ranking of Global Top Targeted Drug ALK Inhibitors for NSCLC Companies by Revenue (US$ Million) in 2021
  • Table 22. Global 5 Largest Players Market Share by Targeted Drug ALK Inhibitors for NSCLC Revenue (CR5 and HHI) & (2017-2022)
  • Table 23. Key Players Headquarters and Area Served
  • Table 24. Key Players Targeted Drug ALK Inhibitors for NSCLC Product Solution and Service
  • Table 25. Date of Enter into Targeted Drug ALK Inhibitors for NSCLC Market
  • Table 26. Mergers & Acquisitions, Expansion Plans
  • Table 27. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
  • Table 28. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Type (2017-2022)
  • Table 29. Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Type (2023-2028) & (US$ Million)
  • Table 30. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Type (2023-2028)
  • Table 31. Global Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
  • Table 32. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Application (2017-2022)
  • Table 33. Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Application (2023-2028) & (US$ Million)
  • Table 34. Global Targeted Drug ALK Inhibitors for NSCLC Revenue Share by Application (2023-2028)
  • Table 35. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
  • Table 36. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
  • Table 37. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
  • Table 38. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
  • Table 39. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
  • Table 40. North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
  • Table 41. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
  • Table 42. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
  • Table 43. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
  • Table 44. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
  • Table 45. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
  • Table 46. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
  • Table 47. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
  • Table 48. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
  • Table 49. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
  • Table 50. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
  • Table 51. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2017-2022) & (US$ Million)
  • Table 52. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2023-2028) & (US$ Million)
  • Table 53. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
  • Table 54. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
  • Table 55. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
  • Table 56. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
  • Table 57. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
  • Table 58. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
  • Table 59. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022) & (US$ Million)
  • Table 60. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028) & (US$ Million)
  • Table 61. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022) & (US$ Million)
  • Table 62. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028) & (US$ Million)
  • Table 63. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022) & (US$ Million)
  • Table 64. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028) & (US$ Million)
  • Table 65. Pfizer Company Details
  • Table 66. Pfizer Business Overview
  • Table 67. Pfizer Targeted Drug ALK Inhibitors for NSCLC Product
  • Table 68. Pfizer Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
  • Table 69. Pfizer Recent Developments
  • Table 70. Novartis Company Details
  • Table 71. Novartis Business Overview
  • Table 72. Novartis Targeted Drug ALK Inhibitors for NSCLC Product
  • Table 73. Novartis Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
  • Table 74. Novartis Recent Developments
  • Table 75. Chugai Pharmaceutical (Hoffmann-La Roche group) Company Details
  • Table 76. Chugai Pharmaceutical (Hoffmann-La Roche group) Business Overview
  • Table 77. Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Product
  • Table 78. Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
  • Table 79. Chugai Pharmaceutical (Hoffmann-La Roche group) Recent Developments
  • Table 80. ARIAD Pharmaceuticals (Takeda) Company Details
  • Table 81. ARIAD Pharmaceuticals (Takeda) Business Overview
  • Table 82. ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Product
  • Table 83. ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
  • Table 84. ARIAD Pharmaceuticals (Takeda) Recent Developments
  • Table 85. Genvio Pharma Limited Company Details
  • Table 86. Genvio Pharma Limited Business Overview
  • Table 87. Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product
  • Table 88. Genvio Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
  • Table 89. Genvio Pharma Limited Recent Developments
  • Table 90. Beacon Pharma Limited Company Details
  • Table 91. Beacon Pharma Limited Business Overview
  • Table 92. Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Product
  • Table 93. Beacon Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
  • Table 94. Beacon Pharma Limited Recent Developments
  • Table 95. Drug International Limted Company Details
  • Table 96. Drug International Limted Business Overview
  • Table 97. Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Product
  • Table 98. Drug International Limted Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
  • Table 99. Drug International Limted Recent Developments
  • Table 100. Incepta Pharmaceuticals Company Details
  • Table 101. Incepta Pharmaceuticals Business Overview
  • Table 102. Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Product
  • Table 103. Incepta Pharmaceuticals Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022) & (US$ Million)
  • Table 104. Incepta Pharmaceuticals Recent Developments
  • Table 105. Research Programs/Design for This Report
  • Table 106. Key Data Information from Secondary Sources
  • Table 107. Key Data Information from Primary Sources

List of Figures

  • Figure 1. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Type: 2021 VS 2028
  • Figure 2. Crizotinib Features
  • Figure 3. Ceritinib Features
  • Figure 4. Alectinib Features
  • Figure 5. Brigatinib Features
  • Figure 6. Lorlatinib Features
  • Figure 7. Other Features
  • Figure 8. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Application: 2021 VS 2028
  • Figure 9. Squamous Cell Carcinoma of NSCLC Case Studies
  • Figure 10. Adenocarcinoma of NSCLC Case Studies
  • Figure 11. Large Cell Carcinoma of NSCLC Case Studies
  • Figure 12. Targeted Drug ALK Inhibitors for NSCLC Report Years Considered
  • Figure 13. Global Targeted Drug ALK Inhibitors for NSCLC Market Size (US$ Million), Year-over-Year: 2017-2028
  • Figure 14. Global Targeted Drug ALK Inhibitors for NSCLC Market Size, (US$ Million), 2017 VS 2021 VS 2028
  • Figure 15. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Region: 2021 VS 2028
  • Figure 16. Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Players in 2021
  • Figure 17. Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Targeted Drug ALK Inhibitors for NSCLC as of 2021)
  • Figure 18. The Top 10 and 5 Players Market Share by Targeted Drug ALK Inhibitors for NSCLC Revenue in 2021
  • Figure 19. North America Targeted Drug ALK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
  • Figure 20. North America Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
  • Figure 21. North America Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
  • Figure 22. North America Targeted Drug ALK Inhibitors for NSCLC Market Size Share by Country (2017-2028)
  • Figure 23. United States Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 24. Canada Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 25. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
  • Figure 26. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
  • Figure 27. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
  • Figure 28. Europe Targeted Drug ALK Inhibitors for NSCLC Market Size Share by Country (2017-2028)
  • Figure 29. Germany Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 30. France Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 31. U.K. Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 32. Italy Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 33. Russia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 34. Nordic Countries Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 35. Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
  • Figure 36. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
  • Figure 37. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
  • Figure 38. Asia Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size Share by Region (2017-2028)
  • Figure 39. China Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 40. Japan Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 41. South Korea Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 42. Southeast Asia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 43. India Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 44. Australia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 45. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
  • Figure 46. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
  • Figure 47. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
  • Figure 48. Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size Share by Country (2017-2028)
  • Figure 49. Mexico Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 50. Brazil Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 51. Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size YoY (2017-2028) & (US$ Million)
  • Figure 52. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Type (2017-2028)
  • Figure 53. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Market Share by Application (2017-2028)
  • Figure 54. Middle East and Africa Targeted Drug ALK Inhibitors for NSCLC Market Size Share by Country (2017-2028)
  • Figure 55. Turkey Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 56. Saudi Arabia Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 57. UAE Targeted Drug ALK Inhibitors for NSCLC Market Size YoY Growth (2017-2028) & (US$ Million)
  • Figure 58. Pfizer Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
  • Figure 59. Novartis Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
  • Figure 60. Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
  • Figure 61. ARIAD Pharmaceuticals (Takeda) Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
  • Figure 62. Genvio Pharma Limited Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
  • Figure 63. Beacon Pharma Limited Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
  • Figure 64. Drug International Limted Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
  • Figure 65. Incepta Pharmaceuticals Revenue Growth Rate in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
  • Figure 66. Bottom-up and Top-down Approaches for This Report
  • Figure 67. Data Triangulation
  • Figure 68. Key Executives Interviewed
目次

Market Analysis and Insights: Global Targeted Drug ALK Inhibitors for NSCLC Market

The global Targeted Drug ALK Inhibitors for NSCLC market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.

Fully considering the economic change by this health crisis, Crizotinib accounting for % of the Targeted Drug ALK Inhibitors for NSCLC global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Squamous Cell Carcinoma of NSCLC segment is altered to an % CAGR throughout this forecast period.

China Targeted Drug ALK Inhibitors for NSCLC market size is valued at US$ million in 2021, while the North America and Europe Targeted Drug ALK Inhibitors for NSCLC are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Targeted Drug ALK Inhibitors for NSCLC landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Targeted Drug ALK Inhibitors for NSCLC market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Targeted Drug ALK Inhibitors for NSCLC market in terms of revenue.

Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Targeted Drug ALK Inhibitors for NSCLC market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Targeted Drug ALK Inhibitors for NSCLC market.

Global Targeted Drug ALK Inhibitors for NSCLC Scope and Market Size

Targeted Drug ALK Inhibitors for NSCLC market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Targeted Drug ALK Inhibitors for NSCLC market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.

Segment by Type

  • Crizotinib
  • Ceritinib
  • Alectinib
  • Brigatinib
  • Lorlatinib
  • Other

Segment by Application

  • Squamous Cell Carcinoma of NSCLC
  • Adenocarcinoma of NSCLC
  • Large Cell Carcinoma of NSCLC

By Company

  • Pfizer
  • Novartis
  • Chugai Pharmaceutical (Hoffmann-La Roche group)
  • ARIAD Pharmaceuticals (Takeda)
  • Genvio Pharma Limited
  • Beacon Pharma Limited
  • Drug International Limted
  • Incepta Pharmaceuticals

By Region

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
    • Nordic Countries
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • South Korea
    • Southeast Asia
    • India
    • Australia
    • Rest of Asia
  • Latin America
    • Mexico
    • Brazil
    • Rest of Latin America
  • Middle East & Africa
    • Turkey
    • Saudi Arabia
    • UAE
    • Rest of MEA

TABLE OF CONTENTS

1 Report Business Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
    • 1.2.2 Crizotinib
    • 1.2.3 Ceritinib
    • 1.2.4 Alectinib
    • 1.2.5 Brigatinib
    • 1.2.6 Lorlatinib
    • 1.2.7 Other
  • 1.3 Market by Application
    • 1.3.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
    • 1.3.2 Squamous Cell Carcinoma of NSCLC
    • 1.3.3 Adenocarcinoma of NSCLC
    • 1.3.4 Large Cell Carcinoma of NSCLC
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Perspective (2017-2028)
  • 2.2 Targeted Drug ALK Inhibitors for NSCLC Growth Trends by Region
    • 2.2.1 Targeted Drug ALK Inhibitors for NSCLC Market Size by Region: 2017 VS 2021 VS 2028
    • 2.2.2 Targeted Drug ALK Inhibitors for NSCLC Historic Market Size by Region (2017-2022)
    • 2.2.3 Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Region (2023-2028)
  • 2.3 Targeted Drug ALK Inhibitors for NSCLC Market Dynamics
    • 2.3.1 Targeted Drug ALK Inhibitors for NSCLC Industry Trends
    • 2.3.2 Targeted Drug ALK Inhibitors for NSCLC Market Drivers
    • 2.3.3 Targeted Drug ALK Inhibitors for NSCLC Market Challenges
    • 2.3.4 Targeted Drug ALK Inhibitors for NSCLC Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Revenue
    • 3.1.1 Global Top Targeted Drug ALK Inhibitors for NSCLC Players by Revenue (2017-2022)
    • 3.1.2 Global Targeted Drug ALK Inhibitors for NSCLC Revenue Market Share by Players (2017-2022)
  • 3.2 Global Targeted Drug ALK Inhibitors for NSCLC Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 3.3 Players Covered: Ranking by Targeted Drug ALK Inhibitors for NSCLC Revenue
  • 3.4 Global Targeted Drug ALK Inhibitors for NSCLC Market Concentration Ratio
    • 3.4.1 Global Targeted Drug ALK Inhibitors for NSCLC Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Targeted Drug ALK Inhibitors for NSCLC Revenue in 2021
  • 3.5 Targeted Drug ALK Inhibitors for NSCLC Key Players Head office and Area Served
  • 3.6 Key Players Targeted Drug ALK Inhibitors for NSCLC Product Solution and Service
  • 3.7 Date of Enter into Targeted Drug ALK Inhibitors for NSCLC Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Targeted Drug ALK Inhibitors for NSCLC Breakdown Data by Type

  • 4.1 Global Targeted Drug ALK Inhibitors for NSCLC Historic Market Size by Type (2017-2022)
  • 4.2 Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Type (2023-2028)

5 Targeted Drug ALK Inhibitors for NSCLC Breakdown Data by Application

  • 5.1 Global Targeted Drug ALK Inhibitors for NSCLC Historic Market Size by Application (2017-2022)
  • 5.2 Global Targeted Drug ALK Inhibitors for NSCLC Forecasted Market Size by Application (2023-2028)

6 North America

  • 6.1 North America Targeted Drug ALK Inhibitors for NSCLC Market Size (2017-2028)
  • 6.2 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type
    • 6.2.1 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022)
    • 6.2.2 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028)
    • 6.2.3 North America Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2017-2028)
  • 6.3 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application
    • 6.3.1 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022)
    • 6.3.2 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028)
    • 6.3.3 North America Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2017-2028)
  • 6.4 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
    • 6.4.1 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022)
    • 6.4.2 North America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028)
    • 6.4.3 U.S.
    • 6.4.4 Canada

7 Europe

  • 7.1 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size (2017-2028)
  • 7.2 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type
    • 7.2.1 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022)
    • 7.2.2 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028)
    • 7.2.3 Europe Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2017-2028)
  • 7.3 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application
    • 7.3.1 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022)
    • 7.3.2 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028)
    • 7.3.3 Europe Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2017-2028)
  • 7.4 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
    • 7.4.1 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022)
    • 7.4.2 Europe Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic Countries

8 Asia-Pacific

  • 8.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size (2017-2028)
  • 8.2 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Type
    • 8.2.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022)
    • 8.2.2 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028)
    • 8.2.3 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2017-2028)
  • 8.3 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Application
    • 8.3.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022)
    • 8.3.2 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028)
    • 8.3.3 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2017-2028)
  • 8.4 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region
    • 8.4.1 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2017-2022)
    • 8.4.2 Asia-Pacific Targeted Drug ALK Inhibitors for NSCLC Market Size by Region (2023-2028)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size (2017-2028)
  • 9.2 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type
    • 9.2.1 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022)
    • 9.2.2 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028)
    • 9.2.3 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2017-2028)
  • 9.3 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application
    • 9.3.1 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022)
    • 9.3.2 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028)
    • 9.3.3 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2017-2028)
  • 9.4 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
    • 9.4.1 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022)
    • 9.4.2 Latin America Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size (2017-2028)
  • 10.2 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Type
    • 10.2.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2017-2022)
    • 10.2.2 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Type (2023-2028)
    • 10.2.3 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Share by Type (2017-2028)
  • 10.3 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Application
    • 10.3.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2017-2022)
    • 10.3.2 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Application (2023-2028)
    • 10.3.3 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Share by Application (2017-2028)
  • 10.4 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country
    • 10.4.1 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2017-2022)
    • 10.4.2 Middle East & Africa Targeted Drug ALK Inhibitors for NSCLC Market Size by Country (2023-2028)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Pfizer
    • 11.1.1 Pfizer Company Details
    • 11.1.2 Pfizer Business Overview
    • 11.1.3 Pfizer Targeted Drug ALK Inhibitors for NSCLC Introduction
    • 11.1.4 Pfizer Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
    • 11.1.5 Pfizer Recent Developments
  • 11.2 Novartis
    • 11.2.1 Novartis Company Details
    • 11.2.2 Novartis Business Overview
    • 11.2.3 Novartis Targeted Drug ALK Inhibitors for NSCLC Introduction
    • 11.2.4 Novartis Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
    • 11.2.5 Novartis Recent Developments
  • 11.3 Chugai Pharmaceutical (Hoffmann-La Roche group)
    • 11.3.1 Chugai Pharmaceutical (Hoffmann-La Roche group) Company Details
    • 11.3.2 Chugai Pharmaceutical (Hoffmann-La Roche group) Business Overview
    • 11.3.3 Chugai Pharmaceutical (Hoffmann-La Roche group) Targeted Drug ALK Inhibitors for NSCLC Introduction
    • 11.3.4 Chugai Pharmaceutical (Hoffmann-La Roche group) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
    • 11.3.5 Chugai Pharmaceutical (Hoffmann-La Roche group) Recent Developments
  • 11.4 ARIAD Pharmaceuticals (Takeda)
    • 11.4.1 ARIAD Pharmaceuticals (Takeda) Company Details
    • 11.4.2 ARIAD Pharmaceuticals (Takeda) Business Overview
    • 11.4.3 ARIAD Pharmaceuticals (Takeda) Targeted Drug ALK Inhibitors for NSCLC Introduction
    • 11.4.4 ARIAD Pharmaceuticals (Takeda) Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
    • 11.4.5 ARIAD Pharmaceuticals (Takeda) Recent Developments
  • 11.5 Genvio Pharma Limited
    • 11.5.1 Genvio Pharma Limited Company Details
    • 11.5.2 Genvio Pharma Limited Business Overview
    • 11.5.3 Genvio Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Introduction
    • 11.5.4 Genvio Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
    • 11.5.5 Genvio Pharma Limited Recent Developments
  • 11.6 Beacon Pharma Limited
    • 11.6.1 Beacon Pharma Limited Company Details
    • 11.6.2 Beacon Pharma Limited Business Overview
    • 11.6.3 Beacon Pharma Limited Targeted Drug ALK Inhibitors for NSCLC Introduction
    • 11.6.4 Beacon Pharma Limited Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
    • 11.6.5 Beacon Pharma Limited Recent Developments
  • 11.7 Drug International Limted
    • 11.7.1 Drug International Limted Company Details
    • 11.7.2 Drug International Limted Business Overview
    • 11.7.3 Drug International Limted Targeted Drug ALK Inhibitors for NSCLC Introduction
    • 11.7.4 Drug International Limted Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
    • 11.7.5 Drug International Limted Recent Developments
  • 11.8 Incepta Pharmaceuticals
    • 11.8.1 Incepta Pharmaceuticals Company Details
    • 11.8.2 Incepta Pharmaceuticals Business Overview
    • 11.8.3 Incepta Pharmaceuticals Targeted Drug ALK Inhibitors for NSCLC Introduction
    • 11.8.4 Incepta Pharmaceuticals Revenue in Targeted Drug ALK Inhibitors for NSCLC Business (2017-2022)
    • 11.8.5 Incepta Pharmaceuticals Recent Developments

12 Analyst's Viewpoints/Conclusions

13 Appendix

  • 13.1 Research Methodology
    • 13.1.1 Methodology/Research Approach
    • 13.1.2 Data Source
  • 13.2 Author Details
  • 13.3 Disclaimer